Anti-Human PDGF-R alpha Therapeutic Antibody (Olaratumab) (CAT#: TAB-192)

Recombinant monoclonal antibody to PDGF-R alpha. Olaratumab is a monoclonal antibody which is for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA

Figure 1 Olaratumab prevents ligand-induced phosphorylation of PDGFRa.

A–C, A-204 and HuO9 cells (A), which only express PDGFRa, G-402 and MG-63 cells (B), which express both PDGF receptors, or G-401 cells (C), which are PDGFRb positive, were treated with 1 mmol/L IgG or olaratumab for 15 minutes and then stimulated with individual PDGFs (5 nmol/L). Whole-cell lysates were probed for phosphorylation of PDGF receptors and downstream effectors AKT and ERK1/2.

Lowery, C. D., Blosser, W., Dowless, M., Knoche, S., Stephens, J., Li, H., ... & Guo, Q. (2018). Olaratumab exerts antitumor activity in preclinical models of pediatric bone and soft tissue tumors through inhibition of platelet-derived growth factor receptor α. Clinical Cancer Research, 24(4), 847-857.

Figure 2 Olaratumab reduces osteosarcoma and MRT cell invasion in vitro.

A–E, A-204 (A), HuO9 (B), G-402 (C), MG-63 (D), or G-401 cells (E) were evaluated for cell invasion using a simplified Boyden chamber assay. Cells were incubated with IgG or olaratumab; individual PDGFs (5 nmol/L each, with the exception of 25 nmol/L PDGF-DD) or FBS served as chemoattractants. After 48 hours, the number of invasive cells was quantified using a fluorescence-based method and normalized to the serum-free media (SFM) IgG control. Results are presented as the summary of duplicate (G-402) or triplicate experiments SEM. P values were calculated using the Student t test. Significance indicators: , P < 0.05, P < 0.001.

Lowery, C. D., Blosser, W., Dowless, M., Knoche, S., Stephens, J., Li, H., ... & Guo, Q. (2018). Olaratumab exerts antitumor activity in preclinical models of pediatric bone and soft tissue tumors through inhibition of platelet-derived growth factor receptor α. Clinical Cancer Research, 24(4), 847-857.

Figure 3 Olaratumab inhibits tumor growth in A-204 and HuO9 cell line–derived xenograft mouse models.

A and B, Mice with A-204 subcutaneous xenografts were treated with either 40 mg/kg IgG control or 40 mg/kg olaratumab three times weekly for 4 weeks. A, Average tumor volume SEM (n ¼ 11/group) during the treatment period is shown. B, Waterfall plot of %Dtumor/control or %regression for individual animals at day 30. One animal in the treatment arm was found dead on day 17 and was not included in downstream analysis. C and D, Mice bearing HuO9 subcutaneous xenografts were treated with olaratumab (60 mg/kg)/1E10 (20 mg/kg) twice weekly and/or cisplatin or doxorubicin (5 mg/kg) once weekly. Treatment began at day 44 (dotted line) and continued for 5 weeks. C, A single HuO9 in vivo experiment is displayed in two separate graphs with the same control and olaratumab/1E10 arms but different chemotherapy-containing arms containing chemotherapy (left, cisplatin; right, doxorubicin). The graph displays average tumor volume SEM (n ¼ 6/group). D, Waterfall plot of individual %Dtumor/control or %regression at day 60. P values for tumor growth curves are displayed in Supplementary Table S4. PD, progressive disease (>10% growth); SD, stable disease ( 50%–10% growth); PR, partial regression ( 50% and>14 mm3).

Lowery, C. D., Blosser, W., Dowless, M., Knoche, S., Stephens, J., Li, H., ... & Guo, Q. (2018). Olaratumab exerts antitumor activity in preclinical models of pediatric bone and soft tissue tumors through inhibition of platelet-derived growth factor receptor α. Clinical Cancer Research, 24(4), 847-857.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • IF, IP, Neut, FuncS, ELISA, FC, ICC
  • CAS
  • 1024603-93-7
  • Generic Name
  • Olaratumab
  • MW
  • 147.2 kDa
  • Related Disease
  • Ovarian cancers

Applications

  • Application Notes
  • The PDGFRA antibody has been reported in applications of WB, Invasion, Inhib.

Target

  • Alternative Names
  • Olaratumab;1024603-93-7;IMC-3G3;IMC3G3;PDGFRA;platelet-derived growth factor receptor, alpha polypeptide;platelet-derived growth factor receptor alpha;CD140a;PDGFR2;PDGFR-alpha;PDGF-R-alpha;CD140a antigen;PDGFRA/BCR fusion;CD140 antigen-like family member

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Resources

Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Olaratumab.

See other products for "Olaratumab"

Afuco™ Anti-PDGFRA ADCC Therapeutic Antibody (Olaratumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to PDGF-R alpha. Olaratumab is a monoclonal antibody which is for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.

See other products for "PDGFRA"


For Research Use Only. Not For Clinical Use.

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
IAImmunoassay
IBImmunoblotting
ICCImmunocytochemistry
IDImmunodiffusion
IFImmunofluorescence
IHCImmunohistochemistry
IHC-FrImmunohistochemistry-Frozen
IHC-PImmunohistochemistry-Paraffin
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
Live cell imagingLive cell imaging
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
MultiplexMultiplex bead-based assay
NeutNeutralization
PPProtein Purification
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
TCTissue Culture
TBTurbidimetry
WBWestern Blot

Send Inquiry

© 2022 Creative BioLabs. All Rights Reserved
  • 0
  • 0

Cart